Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As indicacións xeográficas protexen o nome dun produto orixinario dunha zona xeográfica, á cal lle debe unha determinada calidade, reputación ou outra característica. Descobre que son, en que consiste o seu procedemento de rexistro e que beneficios conceden.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
366
resultados
Última actualización
30/10/2026 [08:23:00]
Resultados 275 a 300 de 366
Resumen de: US20260266805A1
0000 A method of analyzing internal components of an organism, the method comprising a) taking an image of internal components of the organism, while said internal components are contained in vivo, and b) analyzing the internal components. Also a method of determining toxicity or efficacy of a substance, the method comprising: a. exposing an organism to one or more substances of interest; b. taking one or more images of one or more internal components of the organism, c. analyzing internal components of the organism from the images to determine the effects of the substance on the organism, and; d. using the results of the analysis to determine the toxicity or efficacy of the one or more substances.
Resumen de: US20260266811A1
The present invention relates to a method for detecting an analyte in a sample suitable for detecting the analyte over a range of concentrations, the method comprising steps (i)-(v). Thus, the present invention provides a method for detecting an analyte in a sample in which only the reporter reagents in the vicinity of the surface of the substrate results in a signal, the signal being a local region of the optical component in the second optical state. It is the set of local regions of the optical component in the second optical state that are detected.
Resumen de: US20260266825A1
0000 Described herein is a method of immunoassay (the “PRO-C17 assay”) for measuring the levels of type XVII collagen ectodomain present in a patient sample, which method of immunoassay can be used for detecting and/or monitoring cancer and/or assessing the severity thereof in a patient. Also described are monoclonal antibodies and assay kits suitable for use in carrying out said methods.
Resumen de: US20260266810A1
The present invention provides a method for detecting two or more analytes in a sample, the method comprising steps (i)-(v). Thus, the present invention provides a method for detecting two or more analytes in a sample in which only the reporter reagents in the vicinity of the surface of the substrate results in a signal, the signal being a local region of the optical component in the second optical state. It is the set of local regions of the optical component in the second optical state that are detected.
Resumen de: US20260265838A1
0000 Methods of deconvolving a feature profile of a physical system are provided herein. The present method may include: optimizing a regression between a) a feature profile of a first plurality of distinct components and b) a reference matrix of feature signatures for a second plurality of distinct components, wherein the feature profile is modeled as a linear combination of the reference matrix, and wherein the optimizing includes solving a set of regression coefficients of the regression, wherein the solution minimizes 1) a linear loss function and 2) an L2-norm penalty function; and estimating the fractional representation of one or more distinct components among the second plurality of distinct components present in the sample based on the set of regression coefficients. Systems and computer readable media for performing the subject methods are also provided.
Resumen de: US20260264076A1
0000 A multiplexed capillary-flow immunoassay device configured for the simultaneous detection of multiple analytes, specifically, a testing assembly including a detection area, a fluid inlet, and a microfluidic network including at least two microfluidic pathways directed to distinct detection areas each configured to detect a different analyte.
Resumen de: US20260265411A1
0000 Isolated histidyl-tRNA synthetase splice variant polynucleotides and polypeptides having non-canonical biological activities are provided, as well as compositions and methods related thereto.
Resumen de: WO2026187902A1
The present disclosure relates to systems comprising nano-plasmonic chips and methods for the detection of proteins.
Resumen de: WO2026185407A1
The present invention is directed to compositions, including post-biotic compositions, comprising cereal gruel fermented by Lactobacillus plantarum 299 and/or Lactobacillus plantarum 299v®. The compositions are useful for 5 treating diseases in human beings, including liver diseases, as well as gastrointestinal diseases and inflammatory conditions related to liver diseases. Disease treatment and treatment efficacies may be monitored based on the development in selected patient groups of one or more biomarkers, including intestinal fatty acid-binding protein (I-FABP) and C-reactive protein 10 (CRP).
Resumen de: US20260265806A1
Embodiments of the instant disclosure relate to early diagnosis and intervention and/or treatment of neurodegenerative disorders and/or brain damage due to normal aging. Certain embodiments disclosed herein relate to quantifying concentrations of ubiquitin c-terminal hydrolase L1 (UCH-L1) in samples obtained from a subject to assess neuronal cell health and/or diagnose the subject with age-related neuronal cell damage. In some embodiments, a subject can be treated with an effective amount of a therapeutic to stabilize and/or reduce concentrations of UCH-L1 in the subject and treat the subject. In other embodiment, a targeted therapeutic agent, process, or task can be assessed for efficacy of reversing brain aging in a subject.
Resumen de: US20260265365A1
The present disclosure relates to anti-interleukin-11 (IL-11) antibodies and antigen-binding fragments thereof including their use in the treatment or prevention of an IL-11 (interleukin 11) pathway disease or disorder.
Resumen de: US20260266724A1
An apparatus and method for identifying a protein or proteins in a sample of a biofluid. The identification is based on illuminating the sample with ultraviolet radiation and detecting and analyzing the resulting fluorescence. A trained model may be used to determine a protein responsible for a spectra detected from the illumination of the sample.
Resumen de: AU2025223493A1
The present disclosure provides nucleic acids, compositions, and methods of preventing or treating neurodegenerative disease in a subject comprising administering to the subject an agent that targets CHMP2B. In some embodiments the present disclosure provides a method of preventing or decreasing nuclear accumulation of CHMP7 in a cell comprising contacting the cell with an agent that targets expression of CHMP2B in the cell.
Resumen de: AU2024395871A1
The present disclosure provides methods for simultaneously identifying dynamic and disease-associated RNA binding protein (RBP)-RNA interaction (PRI) sites at single nucleotide resolution across the entire transcriptome. The methods disclosed herein recapitulates PRI profiles obtained with several distinct conventional PRI methods in a single assay at efficiencies that are improved by orders of magnitude, and permit the identification of the specific RBP bound at a PRI.
Resumen de: WO2026188004A1
Provided are methods for determining the risk or monitoring the progression of Alzheimer's disease in a subject using expression levels of one or more circRNAs. Also provided are methods for treating a subject identified as having or at risk for Alzheimer's disease.
Resumen de: WO2026187868A1
The present disclosure provides specific anti-ac-tauK174, anti-ac-tauK274, and ac-tauK353 antibodies, or antigen-binding fragments thereof, and methods of their use in diagnosing, differentiating, targeting, staging, prognosing, and/or treating Alzheimer's Disease and related tauopathies, including traumatic brain injury. Methods of identifying a subject having early Alzheimer's Disease and related tauopathies are also provided, the methods comprising detecting proteins using at least one anti-ac-tauK174 antibody, at least one anti-ac-tauK274 antibody, and/or at least one anti-ac-tauK353 antibody. In some embodiments, the subject is ApoE4-positive.
Resumen de: US20260265322A1
0000 Disclosed herein include polynucleotides, expression vectors and compositions enabling expression of a self-assembling proteopathic fusion protein comprising a self-assembling domain fused to a proteopathic polypeptide associated with a proteinopathy. The self-assembling proteopathic fusion protein is capable of forming intracellular protein aggregates that enable robust recapitulation of disease pathology. Provided herein also include methods of using the self-assembling systems disclosed herein to induce proteinopathies (e.g., neurodegenerative diseases) and to screen therapeutic compounds for the treatment of proteinopathies.
Resumen de: WO2026187918A1
Provided herein are systems, devices and methods relating to the diagnosis of traumatic brain injury. A mobile application uses a smartphone camera and an on-device artificial intelligence model to read lateral flow assay test strips and produce a concussion diagnostic result. The application determines whether a concussion biomarker is present in a sample and, when present, calculates a numeric intensity score that reflects the strength of the biomarker signal. Before displaying any result, the application automatically checks the image and test for a set of quality and validity conditions and, if any problem is found, tells the user specifically what went wrong and how to correct it. The application guides users through the entire testing process with a step-by-step interface designed to be usable without clinical training, stores all completed results on the device for longitudinal review, and can optionally receive data from a paired hardware lateral flow assay reader.
Resumen de: WO2026187110A1
The present invention relates to a method for customized diagnosis of patients with acyl coenzyme A overproduction and screening for therapeutic agents for acyl coenzyme A overproduction-associated diseases by using a metabolite having a nucleophilic amine group. The present invention provides a method capable of indirectly identifying the degree of acyl coenzyme A overproduction by measuring an acyl-product generated upon ingestion of a metabolite having a nucleophilic amine group, and thus enables customized diagnosis of patients with acyl coenzyme A overproduction and screening for customized therapeutic agents for diseases caused by acyl coenzyme A overproduction.
Resumen de: US20260266800A1
Systems, devices, and methods herein may include a system for monitoring bodily fluid from a patient. In some embodiments, the system may be configured to collect bodily fluid samples from a patient periodically over time to determine a baseline bodily fluid composition. In some embodiments, the system may use spectrophotometry to determine the baseline bodily fluid composition for the patient. The system may be configured to compare a bodily fluid sample to the baseline bodily fluid composition to detect detecting changes in one or more characteristics of the bodily fluid sample (e.g., composition, absorption spectrum, etc.) from the baseline. Changes in the bodily fluid sample characteristics may be used to predict and/or detect abnormalities or infection for individualized diagnosis.
Resumen de: WO2026185475A1
The invention relates to a method for measuring production and/or reduction of the concentration of a chemical species from a microbiota sample of a subject, the method comprising: - preparing a solution to be analysed by adding a buffer solution to a microbiota sample of a subject; - measuring, with a measuring device, a concentration of the chemical species in the solution to be analysed at an initial time in order to obtain a reference measurement of the concentration of the chemical species in the sample at the initial time; then - carrying out multiple successive measurements of the concentration of the chemical species in the solution to be analysed during a determined period in order to establish a data sequence representing the production and/or the reduction of the chemical species in the solution to be analysed over time, wherein the chemical species is chosen from NO and NO 2 -.
Resumen de: US20260266849A1
0000 Methods for serial amplification of Tau filaments and Tau assemblies include contacting monomeric Tau protein with Tau seed material under conditions permissive for seed-dependent fibril or assembly growth to produce amplified Tau filaments or assemblies, processing at least a portion of the amplified material to generate Tau seed material for further amplification, and repeating the contacting and processing steps to produce serially amplified Tau filaments or assemblies, where the monomeric Tau includes one or more Tau isoforms, variants, fragments, or modified forms. In some embodiments, Tau seed material is obtained from a biological sample associated with a Tauopathy. The methods further include characterizing amplified Tau filaments or assemblies or using the serial amplification process to identify compounds that modulate Tau assembly propagation by comparing propagation characteristics in the presence and absence of a test compound.
Resumen de: WO2026188078A1
The invention relates to quantitative blood-based protein biomarkers and computational methods for detecting and monitoring inner ear disorders and hearing loss. Proteins identified in plasma and extracellular vesicles following noise exposure, ototoxic drug administration, or age-related degeneration are quantified using mass spectrometry, aptamer-based array assays, or immunoassays. Inner ear disorder is identified based on defined fold-change thresholds or multi-biomarker panel performance achieving an AUC of at least 0.75. The invention further provides computer-implemented classification methods and diagnostic kits for early detection and therapeutic monitoring of inner ear disorders.
Resumen de: US20260266814A1
0000 Methods and kits for selectively separating biomolecules in complex samples, such as in blood serum, plasma, and other biological fluids. Metal-organic frameworks (MOFs) are formed around selected biomolecules in a mixture during an in-situ growth process, thereby allowing these biomolecules to be separated more easily from molecules that are not encapsulated by the MOFs. One aspect of the invention separates high-abundance proteins from a biological fluid to enhance the detection and characterization of lower-abundance or harder to detect proteins. This allows the lower-abundance or harder to detect proteins to be more easily detected and accurately analyzed, for example, by mass spectrometry. This is particularly useful in blood samples that contain highly-abundant plasma proteins that interfere with the mass spectrometry analysis of lower-abundant proteins and and protein biomarkers.
Nº publicación: WO2026184869A1 10/09/2026
Solicitante:
UNIV OXFORD INNOVATION LTD [GB]
OXFORD UNIVERSITY INNOVATION LIMITED
Resumen de: WO2026184869A1
The invention relates to using membrane-associated α-synuclein on neuronal-derived extracellular vesicles as a biomarker in the prediction or monitoring of a subject having Parkinson's Disease, and provides methods for determining its level using microfluidics chips.
BOPI
Sede Electrónica
